摘要
目的评估参松养心胶囊治疗病态窦房结综合征的有效性及安全性。方法计算机检索国内外公开发表的文献,通过筛选纳入符合标准的随机对照试验(RCT),经文献筛选及质量评估提取文献相关数据,采用RevMan5.3软件进行分析。结果共纳入8篇中文文献,文献质量等级为B级或C级,共包含394例病态窦房结综合征病人。参松养心胶囊组(治疗组)与对照组(予阿托品、沙丁胺醇、氨茶碱或空白等治疗)比较,两组临床总有效率比较差异有统计学意义[OR=2.82,95%CI(1.73,4.60),P<0.0001];平均心率改善情况比较差异无统计学意义[MD=5.86,95%CI(-2.35,14.08),P=0.16];安全性方面比较差异有统计学意义[OR=0.31,95%CI(0.14,0.68),P=0.004]。结论现有证据表明参松养心胶囊改善病态窦房结综合征总体临床症状较好,在改善平均心率方面不略于对照组,并具有较好的安全性。
Objective To evaluate the efficacy and safety of Shensong Yangxin capsule(SYC)in the treatment of sick sinus syndrome(SSS).Methods The literatures were retrieved by computer,and included in a standard randomized controlled trial.Relevant data were extracted through literature screening and quality assessment,and analyzed with RevMan5.3 software.Results A total of 8 Studies were included.The quality of the literatures were grade B or grade C.A total of 394 patients with sick sinus syndrome were included.Compared with control group(atropine,salbutamol,theophylline or blank),the total effective rate of SYC group was beter[OR=2.82,95%CI(1.73,4.60),P<0.00001].The improvement of mean heart rate was not significant[MD=5.86,95%CI(-2.35,14.08),P=0.16].The safety was significant[OR=0.31,95%CI(0.14,0.68),P=0.004].Conclusion Current evidence showed that SYC is better in improving the overall clinical symptoms of SSS,which is not inferior to the control group in improving the average heart rate,and SYC is safety for SSS.
作者
艾长江
何志凌
徐丹苹
邱楠
王侠
AI Changjiang;HE Zhiling;XU Danping;QIU Nan;WANG Xia(Second Clinical Medical College,Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong,China;Guangdong Provincial Hospital of Chinese Medicine,Guangzhou 510405,Guangdong,China)
出处
《中西医结合心脑血管病杂志》
2020年第11期1684-1689,共6页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金
广东省科学技术厅项目(No.2016A020226011)。